Literature DB >> 23859204

Understanding HIV-1 protease autoprocessing for novel therapeutic development.

Liangqun Huang1, Chaoping Chen.   

Abstract

In the infected cell, HIV-1 protease (PR) is initially synthesized as part of the GagPol polyprotein. PR autoprocessing is a virus-specific process by which the PR domain embedded in the precursor catalyzes proteolytic reactions responsible for liberation of free mature PRs, which then recognize and cleave at least ten different peptide sequences in the Gag and GagPol polyproteins. Despite extensive structure and function studies of the mature PRs as well as the successful development of ten US FDA-approved catalytic-site inhibitors, the precursor autoprocessing mechanism remains an intriguing yet-to-be-solved puzzle. This article discusses current understanding of the autoprocessing mechanism, in an effort to prompt the development of novel anti-HIV drugs that selectively target precursor autoprocessing.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23859204      PMCID: PMC3826259          DOI: 10.4155/fmc.13.89

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  118 in total

1.  Autoprocessing of HIV-1 protease is tightly coupled to protein folding.

Authors:  J M Louis; G M Clore; A M Gronenborn
Journal:  Nat Struct Biol       Date:  1999-09

Review 2.  The choreography of HIV-1 proteolytic processing and virion assembly.

Authors:  Sook-Kyung Lee; Marc Potempa; Ronald Swanstrom
Journal:  J Biol Chem       Date:  2012-10-05       Impact factor: 5.157

Review 3.  Tipranavir: a novel nonpeptidic protease inhibitor of HIV.

Authors:  Jennifer R King; Edward P Acosta
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  On the size of the active site in proteases. I. Papain.

Authors:  I Schechter; A Berger
Journal:  Biochem Biophys Res Commun       Date:  1967-04-20       Impact factor: 3.575

5.  Crystal structures of native and inhibited forms of human cathepsin D: implications for lysosomal targeting and drug design.

Authors:  E T Baldwin; T N Bhat; S Gulnik; M V Hosur; R C Sowder; R E Cachau; J Collins; A M Silva; J W Erickson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

6.  Solution structure of the mature HIV-1 protease monomer: insight into the tertiary fold and stability of a precursor.

Authors:  Rieko Ishima; Dennis A Torchia; Shannon M Lynch; Angela M Gronenborn; John M Louis
Journal:  J Biol Chem       Date:  2003-08-21       Impact factor: 5.157

7.  Novel macromolecular inhibitors of human immunodeficiency virus-1 protease.

Authors:  Gabriella Miklóssy; József Tözsér; János Kádas; Rieko Ishima; John M Louis; Péter Bagossi
Journal:  Protein Eng Des Sel       Date:  2008-05-13       Impact factor: 1.650

8.  Visualizing transient events in amino-terminal autoprocessing of HIV-1 protease.

Authors:  Chun Tang; John M Louis; Annie Aniana; Jeong-Yong Suh; G Marius Clore
Journal:  Nature       Date:  2008-10-02       Impact factor: 49.962

9.  The HIV-1 protease as enzyme and substrate: mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties.

Authors:  A M Mildner; D J Rothrock; J W Leone; C A Bannow; J M Lull; I M Reardon; J L Sarcich; W J Howe; C S Tomich; C W Smith
Journal:  Biochemistry       Date:  1994-08-16       Impact factor: 3.162

10.  Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates.

Authors:  Steve C Pettit; Jeffrey N Lindquist; Andrew H Kaplan; Ronald Swanstrom
Journal:  Retrovirology       Date:  2005-11-01       Impact factor: 4.602

View more
  10 in total

Review 1.  Highly resistant HIV-1 proteases and strategies for their inhibition.

Authors:  Irene T Weber; Daniel W Kneller; Andres Wong-Sam
Journal:  Future Med Chem       Date:  2015       Impact factor: 3.808

2.  Compounds Identified from Marine Mangrove Plant (Avicennia alba) as Potential Antiviral Drug Candidates Against WDSV, an In-Silico Approach.

Authors:  Mohammed Othman Aljahdali; Mohammad Habibur Rahman Molla; Foysal Ahammad
Journal:  Mar Drugs       Date:  2021-04-28       Impact factor: 5.118

3.  A Functional Interplay between Human Immunodeficiency Virus Type 1 Protease Residues 77 and 93 Involved in Differential Regulation of Precursor Autoprocessing and Mature Protease Activity.

Authors:  Christopher J Counts; P Shing Ho; Maureen J Donlin; John E Tavis; Chaoping Chen
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

4.  A modular system to evaluate the efficacy of protease inhibitors against HIV-2.

Authors:  Mohamed Mahdi; Krisztina Matúz; Ferenc Tóth; József Tőzsér
Journal:  PLoS One       Date:  2014-11-24       Impact factor: 3.240

5.  Targeting HIV-1 Protease Autoprocessing for High-throughput Drug Discovery and Drug Resistance Assessment.

Authors:  Liangqun Huang; Linfeng Li; ChihFeng Tien; Daniel V LaBarbera; Chaoping Chen
Journal:  Sci Rep       Date:  2019-01-22       Impact factor: 4.379

Review 6.  Aptamers for Anti-Viral Therapeutics and Diagnostics.

Authors:  Tae-Hyeong Kim; Seong-Wook Lee
Journal:  Int J Mol Sci       Date:  2021-04-17       Impact factor: 5.923

7.  Effects of reduced gag cleavage efficiency on HIV-1 Gag-Pol package.

Authors:  Yi-Ru Lin; Shih-Ming Chu; Fu-Hsien Yu; Kuo-Jung Huang; Chin-Tien Wang
Journal:  BMC Microbiol       Date:  2022-04-09       Impact factor: 3.605

8.  Context-dependent autoprocessing of human immunodeficiency virus type 1 protease precursors.

Authors:  ChihFeng Tien; Liangqun Huang; Susan M Watanabe; Jordan T Speidel; Carol A Carter; Chaoping Chen
Journal:  PLoS One       Date:  2018-01-16       Impact factor: 3.240

9.  Inhibition of the precursor and mature forms of HIV-1 protease as a tool for drug evaluation.

Authors:  Jana Humpolíčková; Jan Weber; Jana Starková; Eva Mašínová; Jana Günterová; Iva Flaisigová; Jan Konvalinka; Taťána Majerová
Journal:  Sci Rep       Date:  2018-07-11       Impact factor: 4.379

10.  Acquired HIV-1 Protease Conformational Flexibility Associated with Lopinavir Failure May Shape the Outcome of Darunavir Therapy after Antiretroviral Therapy Switch.

Authors:  Simeon Eche; Ajit Kumar; Nelson Sonela; Michelle L Gordon
Journal:  Biomolecules       Date:  2021-03-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.